INTEGRA LIFESCIENCES HOLDINGS CORP (IART) FY2026 Q2 P&L / Income Statement

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue, net

418,761,000 US dollars

Cost of goods sold

199,017,000 US dollars

Gross profit (calculated)

219,744,000 US dollars

Operating expenses (calculated)

200,459,000 US dollars

Operating income (loss)

19,285,000 US dollars

Other income (expense), net (calculated)

negative 14,541,000 US dollars

Income (loss) before income taxes

4,744,000 US dollars

Provision (benefit) for income taxes

262,000 US dollars

Net income (loss)

4,482,000 US dollars

Specialty Surgery - ENT Solutions

41,199,000 US dollars

Specialty Surgery - Neurosurgery

213,264,000 US dollars

Specialty Surgery - Surgical Instruments

54,806,000 US dollars

Tissue Reconstruction - Private Label

28,187,000 US dollars

Tissue Reconstruction - Wound Reconstruction Solutions

81,305,000 US dollars

Research and development

24,253,000 US dollars

Selling, general and administrative

172,436,000 US dollars

Intangible asset amortization

3,770,000 US dollars

Goodwill impairment charge

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.